PTGX
Price
$55.25
Change
+$0.81 (+1.49%)
Updated
Jun 26, 04:59 PM (EDT)
Capitalization
3.42B
34 days until earnings call
TRVI
Price
$5.65
Change
-$0.03 (-0.53%)
Updated
Jun 26, 04:59 PM (EDT)
Capitalization
689.13M
41 days until earnings call
Interact to see
Advertisement

PTGX vs TRVI

Header iconPTGX vs TRVI Comparison
Open Charts PTGX vs TRVIBanner chart's image
Protagonist Therapeutics
Price$55.25
Change+$0.81 (+1.49%)
Volume$14.55K
Capitalization3.42B
Trevi Therapeutics
Price$5.65
Change-$0.03 (-0.53%)
Volume$60.66K
Capitalization689.13M
PTGX vs TRVI Comparison Chart in %
Loading...
PTGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TRVI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PTGX vs. TRVI commentary
Jun 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PTGX is a StrongBuy and TRVI is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 27, 2025
Stock price -- (PTGX: $55.22 vs. TRVI: $5.66)
Brand notoriety: PTGX and TRVI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PTGX: 94% vs. TRVI: 55%
Market capitalization -- PTGX: $3.42B vs. TRVI: $689.13M
PTGX [@Biotechnology] is valued at $3.42B. TRVI’s [@Biotechnology] market capitalization is $689.13M. The market cap for tickers in the [@Biotechnology] industry ranges from $301.01B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PTGX’s FA Score shows that 1 FA rating(s) are green whileTRVI’s FA Score has 0 green FA rating(s).

  • PTGX’s FA Score: 1 green, 4 red.
  • TRVI’s FA Score: 0 green, 5 red.
According to our system of comparison, PTGX is a better buy in the long-term than TRVI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PTGX’s TA Score shows that 5 TA indicator(s) are bullish while TRVI’s TA Score has 2 bullish TA indicator(s).

  • PTGX’s TA Score: 5 bullish, 5 bearish.
  • TRVI’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, PTGX is a better buy in the short-term than TRVI.

Price Growth

PTGX (@Biotechnology) experienced а +2.40% price change this week, while TRVI (@Biotechnology) price change was -6.75% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.59%. For the same industry, the average monthly price growth was +34.25%, and the average quarterly price growth was +14.95%.

Reported Earning Dates

PTGX is expected to report earnings on Jul 31, 2025.

TRVI is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+3.59% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PTGX($3.42B) has a higher market cap than TRVI($689M). PTGX YTD gains are higher at: 43.044 vs. TRVI (37.379). PTGX has higher annual earnings (EBITDA): 30.1M vs. TRVI (-47.23M). PTGX has more cash in the bank: 574M vs. TRVI (103M). TRVI has less debt than PTGX: TRVI (957K) vs PTGX (11.4M). PTGX has higher revenues than TRVI: PTGX (208M) vs TRVI (0).
PTGXTRVIPTGX / TRVI
Capitalization3.42B689M497%
EBITDA30.1M-47.23M-64%
Gain YTD43.04437.379115%
P/E Ratio70.79N/A-
Revenue208M0-
Total Cash574M103M557%
Total Debt11.4M957K1,191%
FUNDAMENTALS RATINGS
PTGX vs TRVI: Fundamental Ratings
PTGX
TRVI
OUTLOOK RATING
1..100
2261
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
56
Fair valued
PROFIT vs RISK RATING
1..100
4566
SMR RATING
1..100
5597
PRICE GROWTH RATING
1..100
3943
P/E GROWTH RATING
1..100
2100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TRVI's Valuation (56) in the Pharmaceuticals Major industry is in the same range as PTGX (79) in the Biotechnology industry. This means that TRVI’s stock grew similarly to PTGX’s over the last 12 months.

PTGX's Profit vs Risk Rating (45) in the Biotechnology industry is in the same range as TRVI (66) in the Pharmaceuticals Major industry. This means that PTGX’s stock grew similarly to TRVI’s over the last 12 months.

PTGX's SMR Rating (55) in the Biotechnology industry is somewhat better than the same rating for TRVI (97) in the Pharmaceuticals Major industry. This means that PTGX’s stock grew somewhat faster than TRVI’s over the last 12 months.

PTGX's Price Growth Rating (39) in the Biotechnology industry is in the same range as TRVI (43) in the Pharmaceuticals Major industry. This means that PTGX’s stock grew similarly to TRVI’s over the last 12 months.

PTGX's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for TRVI (100) in the Pharmaceuticals Major industry. This means that PTGX’s stock grew significantly faster than TRVI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PTGXTRVI
RSI
ODDS (%)
Bearish Trend 2 days ago
69%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 21 days ago
81%
Declines
ODDS (%)
Bearish Trend 7 days ago
77%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
82%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
PTGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TRVI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
CGMM26.710.27
+1.02%
Capital Group U.S. Small & Mid Cap ETF
NVDU95.650.93
+0.98%
Direxion Daily NVDA Bull 2X Shares
IEV62.580.51
+0.82%
iShares Europe ETF
ZECP31.560.22
+0.69%
Zacks Earnings Consistent ETF
PFIG24.010.05
+0.21%
Invesco Fdmtl Invmt Grd Corp Bd ETF

PTGX and

Correlation & Price change

A.I.dvisor indicates that over the last year, PTGX has been closely correlated with BIESF. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if PTGX jumps, then BIESF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PTGX
1D Price
Change %
PTGX100%
+1.42%
BIESF - PTGX
66%
Closely correlated
N/A
MLYS - PTGX
51%
Loosely correlated
-1.69%
TRVI - PTGX
44%
Loosely correlated
-0.35%
DNLI - PTGX
41%
Loosely correlated
+0.28%
ORMP - PTGX
37%
Loosely correlated
-0.46%
More

TRVI and

Correlation & Price change

A.I.dvisor indicates that over the last year, TRVI has been loosely correlated with PTGX. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if TRVI jumps, then PTGX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TRVI
1D Price
Change %
TRVI100%
-0.35%
PTGX - TRVI
44%
Loosely correlated
+1.42%
BIESF - TRVI
42%
Loosely correlated
N/A
MLYS - TRVI
31%
Poorly correlated
-1.69%
QURE - TRVI
30%
Poorly correlated
-0.70%
GOSS - TRVI
29%
Poorly correlated
-4.41%
More